Introduction: The persistent inflammation that characterizes COPD and affects its natural course also impacting on symptoms has prompted research to find molecules that can regulate the inflammatory process but still available anti-inflammatory therapies provide little or no benefit in COPD patients. Consequently, numerous anti-inflammatory molecules that are effective in animal models of COPD have been or are being evaluated in humans. Areas covered: In this article we describe several classes of drugs that target the cellular components of inflammation under clinical development for COPD. Expert opinion: Although the results of many clinical trials with new molecules have often been disappointing, several studies are underway to investigate whether some of these molecules may be effective in treating specific subgroups of COPD patients. Indeed, the current perspective is to apply a more personalized treatment to the patient. This means being able to better define the patient’s inflammatory state and treat it in a targeted manner. Unfortunately, the difficulty in translating encouraging experimental data into human clinical trials, the redundancy in the effects induced by signal-transmitting substances and the nonspecific effects of many classes that are undergoing clinical trials, do not yet allow specific inflammatory cell types to be targeted.
Classes of drugs that target the cellular components of inflammation under clinical development for COPD / Matera, M. G.; Calzetta, L.; Annibale, R.; Russo, F.; Cazzola, M.. - In: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. - ISSN 1751-2433. - 14:8(2021), pp. 1015-1027. [10.1080/17512433.2021.1925537]
|Appare nelle tipologie:||1.1 Articolo su rivista|